HLA-B27 Misfolding an the UPR in Spondyloarthritis

脊柱关节炎中的 HLA-B27 错误折叠和 UPR

基本信息

  • 批准号:
    7650283
  • 负责人:
  • 金额:
    $ 40.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-08-24 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): HLA-B27 (B27) is responsible for a large proportion of the genetic susceptibility to spondyloarthritis, particularly ankylosing spondylitis. Despite improvements in the treatment of these diseases, therapy remains inadequate and requires continual use of medications that carry definite risks. It is expected that a better understanding of pathogenic mechanisms, and specifically the role of B27, will lead to improved interventions and possibly a means of prevention. Studies funded by this grant have shown that B27 is a protein that misfolds. Using an animal model of spondyloarthritis, where HLA-B27 is expressed in rats (B27-Tg rats), we have shown that B27 misfolding causes stress in the endoplasmic reticulum (ER) of the cell, which in turn activates what is known as the unfolded protein response (UPR). Preliminary findings indicate that the B27-induced UPR causes macrophages to strongly overexpress a group of cytokines when stimulated by Toll-like receptor (TLR) ligands. We refer to this a UPR-TLR synergy. TLRs are pattern recognition receptors that allow cells to sense and respond to microbial products, and they play an important role in linking innate and adaptive immune responses. The cytokines overproduced by cells undergoing an B27-induced UPR may promote a chronic immune deviation resulting in inflammation, linking protein misfolding to an inflammatory disease. The studies proposed in Aim 1 will determine the effects of B27-induced UPR activation on the production of cytokines in immunoregulatory cells including macrophages and dendritic cells, and establish the UPR component of UPR-TLR synergy. In Aim 2 we will test whether UPR-TLR synergy causes activation of CD4+ T cells, and establish whether this occurs in B27-Tg rats during the development of inflammation. Studies in Aim 3 use a transgenic approach to modulate the HLA-B27-induced UPR to determine its role in inflammation. Downstream cytokines overproduced as a result of UPR-TLR synergy will also be targeted using a knockdown approach to determine their role in disease. These studies will significantly advance our understanding of HLA-B27 misfolding and the UPR in an animal model of spondyloarthritis. This work has the potential to drive translational studies in humans, and lead to the development of novel therapies targeting this pathological response.
描述(由申请人提供):HLA-B27(B27)是脊柱关节炎,特别是强直性脊柱炎遗传易感性的主要原因。尽管这些疾病的治疗有所改进,但治疗仍然不足,需要持续使用具有明确风险的药物。预计更好地了解致病机制,特别是B27的作用,将导致改善干预措施,并可能成为预防手段。这项资助的研究表明,B27是一种错误折叠的蛋白质。使用脊椎关节炎的动物模型,其中HLA-B27在大鼠(B27-Tg大鼠)中表达,我们已经表明B27错误折叠导致细胞内质网(ER)中的应激,这反过来激活了所谓的未折叠蛋白反应(UPR)。初步研究结果表明,B27诱导的UPR导致巨噬细胞在Toll样受体(TLR)配体刺激时强烈过表达一组细胞因子。我们将此称为UPR-TLR协同作用。TLR是模式识别受体,允许细胞感知和响应微生物产物,并且它们在连接先天性和适应性免疫应答中发挥重要作用。经历B27诱导的UPR的细胞过度产生的细胞因子可能促进慢性免疫偏离,导致炎症,将蛋白质错误折叠与炎性疾病联系起来。目的1中提出的研究将确定B27诱导的UPR活化对免疫调节细胞(包括巨噬细胞和树突状细胞)中细胞因子产生的影响,并建立UPR-TLR协同作用的UPR组分。在目的2中,我们将测试UPR-TLR协同作用是否引起CD 4 + T细胞的活化,并确定这是否在炎症发展期间发生在B27-Tg大鼠中。目的3中的研究使用转基因方法来调节HLA-B27诱导的UPR以确定其在炎症中的作用。由于UPR-TLR协同作用而过度产生的下游细胞因子也将使用敲低方法靶向,以确定它们在疾病中的作用。这些研究将显著推进我们对脊椎关节炎动物模型中HLA-B27错误折叠和UPR的理解。这项工作有可能推动人类的转化研究,并导致针对这种病理反应的新型疗法的开发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THOMAS A GRIFFIN其他文献

THOMAS A GRIFFIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THOMAS A GRIFFIN', 18)}}的其他基金

Role of Immunoproteasomes in Activated T Cell Apoptosis
免疫蛋白酶体在活化 T 细胞凋亡中的作用
  • 批准号:
    7497900
  • 财政年份:
    2007
  • 资助金额:
    $ 40.42万
  • 项目类别:
Role of Type I Interferons in a Self-Sustaining Murine Model of Myositis
I 型干扰素在肌炎自我维持小鼠模型中的作用
  • 批准号:
    7356623
  • 财政年份:
    2007
  • 资助金额:
    $ 40.42万
  • 项目类别:
Role of Immunoproteasomes in Activated T Cell Apoptosis
免疫蛋白酶体在活化 T 细胞凋亡中的作用
  • 批准号:
    7237115
  • 财政年份:
    2007
  • 资助金额:
    $ 40.42万
  • 项目类别:
Role of Type I Interferons in a Self-Sustaining Murine Model of Myositis
I 型干扰素在肌炎自我维持小鼠模型中的作用
  • 批准号:
    7497909
  • 财政年份:
    2007
  • 资助金额:
    $ 40.42万
  • 项目类别:
Propeptide Mediation of Immunoproteasome Assembly
免疫蛋白酶体组装的前肽介导
  • 批准号:
    6879175
  • 财政年份:
    2003
  • 资助金额:
    $ 40.42万
  • 项目类别:
Propeptide Mediation of Immunoproteasome Assembly
免疫蛋白酶体组装的前肽介导
  • 批准号:
    6597811
  • 财政年份:
    2003
  • 资助金额:
    $ 40.42万
  • 项目类别:
Propeptide Mediation of Immunoproteasome Assembly
免疫蛋白酶体组装的前肽介导
  • 批准号:
    7055372
  • 财政年份:
    2003
  • 资助金额:
    $ 40.42万
  • 项目类别:
Propeptide Mediation of Immunoproteasome Assembly
免疫蛋白酶体组装的前肽介导
  • 批准号:
    6739021
  • 财政年份:
    2003
  • 资助金额:
    $ 40.42万
  • 项目类别:
HLA-B27 Misfolding an the UPR in Spondyloarthritis
脊柱关节炎中的 HLA-B27 错误折叠和 UPR
  • 批准号:
    7462451
  • 财政年份:
    2000
  • 资助金额:
    $ 40.42万
  • 项目类别:
HLA-B27 Misfolding an the UPR in Spondyloarthritis
脊柱关节炎中的 HLA-B27 错误折叠和 UPR
  • 批准号:
    7876705
  • 财政年份:
    2000
  • 资助金额:
    $ 40.42万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 40.42万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 40.42万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 40.42万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 40.42万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 40.42万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 40.42万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 40.42万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 40.42万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 40.42万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 40.42万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了